Phase III study of ciclesonide nasal aerosol (74ug and 148ug in the morning) in patients 12 years or older with seasonal allergic rhinitis.

Trial Profile

Phase III study of ciclesonide nasal aerosol (74ug and 148ug in the morning) in patients 12 years or older with seasonal allergic rhinitis.

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Feb 2013

At a glance

  • Drugs Ciclesonide (Primary)
  • Indications Seasonal allergic rhinitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Feb 2013 Results from a post-hoc analysis, which included data from this trial, have been presented at the 2013 Annual Meeting of the American Academy of Allergy, Asthma and Immunology according to a Sunovion Pharmaceuticals media release.
    • 28 Nov 2012 New trial record
    • 12 Nov 2012 Results were presented at the 2012 Annual Meeting of the American College of Allergy, Asthma and Immunology (ACAAI), according to a Sunovion Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top